Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2

Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular targets.

The discussion centered on a pipeline of antibody‑drug conjugates aimed at novel antigens, with particular attention to TROPE2 and other emerging targets. These agents are being designed to deliver cytotoxic payloads directly to tumor cells expressing the new markers.

By targeting proteins not covered by existing HER2‑based treatments, these ADCs could provide therapeutic options for patients who do not meet the narrow biomarker criteria required for current therapies, potentially widening the treatable patient population.